Fig. 3From: Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study)LS mean change from baseline in peak inspiratory capacity after 21Â days, overall and for each treatment period (full analysis set)Back to article page